The real cost of pediatric Crohn's disease: the role of infliximab in the treatment of pediatric IBD.
Marsha
M
Kay
Robert
R
Wyllie
D000367:Age Factors; D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use*; D002648:Child; D017281:Cost of Illness; D003424:Crohn Disease / Q000150:complications* / Q000188:drug therapy* / Q000191:economics; D016527:Drug Costs; D005765:Gastrointestinal Agents / Q000191:economics* / Q000627:therapeutic use*; D006130:Growth Disorders / Q000191:economics / Q000209:etiology* / Q000517:prevention & control*; D006801:Humans; D000069285:Infliximab
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab